Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder

NCT05626959 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Autism Spectrum Disorder

Interventions

DRUG: NTI164

Sponsor

Fenix Innovation Group

Collaborators

[object Object]
[object Object]